Imatinib reduces non-alcoholic fatty liver disease in obese mice by targeting inflammatory and lipogenic pathways in macrophages and liver

Macrophages have been recognized as key players in non-alcoholic fatty liver disease (NAFLD). Our aim was to assess whether pharmacological attenuation of macrophages can be achieved by imatinib, an anti-leukemia drug with known anti-inflammatory and anti-diabetic properties, and how this impacts on...

Descripción completa

Detalles Bibliográficos
Autores principales: AlAsfoor, Shefaa, Rohm, Theresa V., Bosch, Angela J. T., Dervos, Thomas, Calabrese, Diego, Matter, Matthias S., Weber, Achim, Cavelti-Weder, Claudia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6193017/
https://www.ncbi.nlm.nih.gov/pubmed/30333571
http://dx.doi.org/10.1038/s41598-018-32853-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6193017/
https://www.ncbi.nlm.nih.gov/pubmed/30333571
http://dx.doi.org/10.1038/s41598-018-32853-w

Ejemplares similares